Definium Therapeutics announced positive topline results from its Emerge Phase 3 study of DT120 ODT 100 microgram for major depressive disorder. The trial met its primary endpoint with a statistically significant improvement in MADRS total score at Week 6, showing an LS mean change of -13.3 for DT120 ODT versus -5.2 for placebo, a difference of -8.1 points. Rapid activity was observed with a placebo-adjusted reduction of -14.2 points at Week 1, and durable effects with a -7.3-point reduction at Week 12. Following the update, Robert W. Baird analyst Christopher Chen raised the price target on Definium Therapeutics to $57 from $37 while maintaining an Outperform rating.
Definium Therapeutics, Inc.Positive Phase 3 trial results for DT120 ODT in major depressive disorder meeting primary endpoint